Andrea Kay

13.8k total citations · 3 hit papers
46 papers, 7.6k citations indexed

About

Andrea Kay is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Andrea Kay has authored 46 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 17 papers in Molecular Biology and 15 papers in Oncology. Recurrent topics in Andrea Kay's work include Renal cell carcinoma treatment (16 papers), Cancer Genomics and Diagnostics (10 papers) and Renal and related cancers (6 papers). Andrea Kay is often cited by papers focused on Renal cell carcinoma treatment (16 papers), Cancer Genomics and Diagnostics (10 papers) and Renal and related cancers (6 papers). Andrea Kay collaborates with scholars based in United States, Switzerland and Germany. Andrea Kay's co-authors include Bernard Escudier, Robert J. Motzer, Alain Ravaud, Norbert Hollaender, Thomas E. Hutson, Sergio Bracarda, Camillo Porta, Stéphane Oudard, Robert A. Figlin and John A. Thompson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Andrea Kay

46 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

2008 2.3k citations Robert J. Motzer, Bernard Escudier et al. The Lancet profile →
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

2003 2.1k citations Andrea Kay et al. profile →
Phase 3 trial of everolimus for metastatic renal cell carcinoma

2010 903 citations Robert J. Motzer, Bernard Escudier et al. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrea Kay United States	23	4.7k	3.7k	3.2k	1.8k	758	46	7.6k
Viktor Grünwald Germany	41	6.8k 1.4×	5.5k 1.5×	4.1k 1.3×	3.0k 1.7×	367 0.5×	328	10.4k
Gary R. Hudes United States	40	6.8k 1.5×	6.1k 1.7×	3.5k 1.1×	3.6k 2.0×	351 0.5×	102	10.7k
David Lebwohl United States	26	3.3k 0.7×	3.4k 0.9×	5.3k 1.6×	1.7k 0.9×	1.1k 1.5×	43	9.6k
Isan Chen United States	16	7.0k 1.5×	4.8k 1.3×	3.6k 1.1×	3.1k 1.7×	179 0.2×	41	9.1k
Bijoyesh Mookerjee United States	30	2.2k 0.5×	4.1k 1.1×	3.7k 1.1×	2.3k 1.3×	194 0.3×	85	7.4k
Sindy T. Kim United States	16	8.4k 1.8×	5.9k 1.6×	4.6k 1.4×	3.9k 2.2×	219 0.3×	22	10.9k
Sergio Bracarda Italy	38	7.6k 1.6×	5.8k 1.6×	4.4k 1.4×	3.8k 2.1×	420 0.6×	236	11.6k
Theodore F. Logan United States	37	3.2k 0.7×	3.3k 0.9×	4.5k 1.4×	1.5k 0.8×	138 0.2×	120	8.0k
Apurva A. Desai United States	21	4.0k 0.9×	3.9k 1.1×	2.5k 0.8×	2.2k 1.2×	147 0.2×	36	6.8k
Jennifer J. Wheler United States	42	1.8k 0.4×	3.2k 0.9×	2.6k 0.8×	2.1k 1.1×	208 0.3×	199	6.7k

Countries citing papers authored by Andrea Kay

Since Specialization

Citations

This map shows the geographic impact of Andrea Kay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Kay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Kay more than expected).

Fields of papers citing papers by Andrea Kay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Kay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Kay. The network helps show where Andrea Kay may publish in the future.

Co-authorship network of co-authors of Andrea Kay

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Kay. A scholar is included among the top collaborators of Andrea Kay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Kay. Andrea Kay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

André, Fabrice, Thomas Bachelot, Mario Campone, et al.. (2013). Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer. Clinical Cancer Research. 19(13). 3693–3702. 251 indexed citations

Angevin, Eric, José A. López-Martín, Chia‐Chi Lin, et al.. (2013). Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 19(5). 1257–1268. 103 indexed citations

Kay, Andrea, John Higgins, Andrew G. Day, Ralph M. Meyer, & Christopher M. Booth. (2011). Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. Annals of Oncology. 23(6). 1646–1651. 49 indexed citations

Kay, Andrea, et al.. (2011). An unexpected case of coumarin poisoning with coumatetralyl. BMJ Case Reports. 2011. bcr0520102992–bcr0520102992. 2 indexed citations

White, Dorothy A., Philippe Camus, Masahiro Endo, et al.. (2010). Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma. American Journal of Respiratory and Critical Care Medicine. 182(3). 396–403. 156 indexed citations

Motzer, Robert J., Bernard Escudier, Stéphane Oudard, et al.. (2010). Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer. 116(18). 4256–4265. 903 indexed citations breakdown →

Yuan, Ruirong, Andrea Kay, William J. Berg, & David Lebwohl. (2009). Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. Journal of Hematology & Oncology. 2(1). 45–45. 188 indexed citations

Lebwohl, David, et al.. (2009). Progression-Free Survival. The Cancer Journal. 15(5). 386–394. 42 indexed citations

Motzer, Robert J., Bernard Escudier, Stéphane Oudard, et al.. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet. 372(9637). 449–456. 2339 indexed citations breakdown →

10.

Motzer, Robert J., Bernard Escudier, Stéphane Oudard, et al.. (2008). RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC)after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase-III study. Journal of Clinical Oncology. 26(15_suppl). LBA5026–LBA5026. 42 indexed citations

11.

Marbach, Peter, W. Bauer, David Bodmer, et al.. (2006). Discovery and Development of Somatostatin Agonists. Kluwer Academic Publishers eBooks. 11. 183–209. 5 indexed citations

12.

Blackledge, G., et al.. (2000). Anti-EGF receptor therapy. Prostate Cancer and Prostatic Diseases. 3(4). 296–302. 15 indexed citations

13.

Sulkowski, U., Markus W. Büchler, P. Pederzoli, et al.. (1999). A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma. European Journal of Cancer. 35(13). 1805–1808. 12 indexed citations

14.

Kay, Andrea, Alan Saven, Dennis A. Carson, et al.. (1992). 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.. Journal of Clinical Oncology. 10(3). 371–377. 149 indexed citations

15.

Rosenbloom, Barry E., Andrea Kay, Paul Garver, et al.. (1992). A Less Costly Regimen of Alglucerase to Treat Gaucher's Disease. New England Journal of Medicine. 327(23). 1632–1636. 105 indexed citations

16.

Kay, Andrea & Ernest Beutler. (1992). The effect of ammonium, phosphate, potassium, and hypotonicity on stored red cells. Transfusion. 32(1). 37–41. 13 indexed citations

17.

Kay, Andrea, Lawrence A. Solberg, Douglas A. Nichols, & Robert M. Petitt. (1991). Prognostic Significance of Computed Tomography of the Brain in Thrombotic Thrombocytopenic Purpura. Mayo Clinic Proceedings. 66(6). 602–607. 17 indexed citations

18.

Beutler, Ernest, Andrea Kay, Alan Saven, et al.. (1991). Enzyme replacement therapy for Gaucher disease. Blood. 78(5). 1183–1189. 138 indexed citations

19.

Beutler, Ernest, Lawrence D. Piro, Alan Saven, et al.. (1991). 2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside. Leukemia & lymphoma. 5(1). 1–8. 79 indexed citations

20.

Kay, Andrea. (1973). Depression of bone marrow and thrombocytopenia associated with chrysotherapy.. Annals of the Rheumatic Diseases. 32(3). 277–278. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact